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1. Introduction {#sec001}
===============

Understanding the relationship between phenotype and genotype in the clinical setting is one of the main objectives of traditional research \[[@pone.0174637.ref001]\]. However, studies on a large number of mutations are problematic, primarily due to the experimental analyses. In contrast, *in silico* analysis is faster and easier to execute, yields more results, and costs less, thus making it more efficient. This type of analysis is based on alterations in the sequences of nucleotides and/or amino acids and their comparison with the native sequence to correlate the effect of these alterations on the phenotype of the individual \[[@pone.0174637.ref001],[@pone.0174637.ref002],[@pone.0174637.ref003],[@pone.0174637.ref004]\].

Mutations in the *HBB* gene, which is located on chromosome 11 p15.5 \[[@pone.0174637.ref005]\], are responsible for several serious hemoglobinopathies, such as sickle cell anemia and β-thalassemia. Hemoglobinopathies are a set of hereditary diseases caused by the abnormal structure or insufficient production of hemoglobin. Sickle cell anemia and β-thalassemia can lead to serious anemia and other life threatening conditions \[[@pone.0174637.ref006]\]. Sickle cell anemia is one of the most common monogenic diseases worldwide. It is estimated that 312,000 people are born with sickle cell anemia every year, and the majority of these individuals are native to Sub-Saharan Africa \[[@pone.0174637.ref007]\]. Thus, it is important for the public healthcare system to detect heterozygous carriers of hemoglobinopathies, as they can produce homozygous and double heterozygous individuals with serious clinical conditions \[[@pone.0174637.ref008]\].

The 1,000 Genomes Project is an international consortium organized with the objective of sequencing a large number of individual genomes representative of the world's population. The consortium has the objective of better characterizing the sequence variation of the human genome and enabling the investigation of the relationship between genotype and phenotype. Thus, the 1,000 Genomes Project enables a more precise study of variants in genome-wide association studies (GWAS) and the best localization of variants associated with diseases in different population groups \[[@pone.0174637.ref009]\].

The objective of this study is to track variations in the β-globin gene (*HBB*); to describe the frequencies of mutations in different population groups using the 1,000 Genomes databank, which provides a comprehensive resource of human genetic variation \[[@pone.0174637.ref009]\] relative to the HG19 reference genome \[[@pone.0174637.ref010]\]; and to investigate the pattern of resulting pathogenicity.

2. Methodology {#sec002}
==============

To perform this study, data from 2,504 samples deposited in the 1,000 Genomes database were used; these open-access sequences were aligned with the HG19 reference genome using the SNPEFF tool \[[@pone.0174637.ref011]\]. This program provides and records the effects both of genetic variations as well as amino acid alterations. The resulting data were visualized in the Integrative Genomics Viewer (IGV) \[[@pone.0174637.ref012]\], a high-performance visualization tool for the interactive exploration of genomic datasets. The mutations were tracked at the nucleotide and amino acid levels, and the population frequencies with which these mutations occur, the type of mutation, and the respective positions were recorded.

To investigate pathogenicity these mutations, five different prediction tools, including POLYPHEN \[[@pone.0174637.ref013]\], SIFT \[[@pone.0174637.ref014]\], PROVEAN \[[@pone.0174637.ref015]\], PANTHER \[[@pone.0174637.ref016]\], and E MUTPRED \[[@pone.0174637.ref017]\], and three databanks, including CLINVAR \[[@pone.0174637.ref018]\], dbSNP \[[@pone.0174637.ref019]\] and HbVar \[[@pone.0174637.ref020]\], were used, as shown in [Fig 1](#pone.0174637.g001){ref-type="fig"}.

![Alignment of the 1000 Genomes and HG19 sequences of *HBB* using the SNPEFF tool; predictors and BD used for the investigation of pathogenic mutations.](pone.0174637.g001){#pone.0174637.g001}

Each predictor uses distinct characteristics to determine the effect of the mutations in relation to the information obtained regarding the structure and function of the protein. It is important to highlight that the results of all predictors provide additional evidence of pathogenicity; thus, five predictors were analyzed to improve accuracy. The determination of the pathogenicity of each mutation is based on four pieces of evidence: (i) CLINVAR, (ii) dbSNP, (iii) HbVar, and (iv) predictors.

Tables [1](#pone.0174637.t001){ref-type="table"}, [2](#pone.0174637.t002){ref-type="table"} and [3](#pone.0174637.t003){ref-type="table"} present the following results of the alignment of sequences from 2,504 samples: (1) the positions in the genome; (2) the identification of the single nucleotide polymorphism (SNP) of each mutation; (3) the types of mutations; (4) the mutations observed at the nucleotide level; (5) the respective consequences at the amino acid level; (6) the population frequency of each mutation; and (7) the pathogenicity investigated for each mutation.

10.1371/journal.pone.0174637.t001

###### Position and SNP ID of the mutations observed at the nucleotide level, the respective consequences at the amino acid level, the types of mutations, and the number of individuals.

![](pone.0174637.t001){#pone.0174637.t001g}

  Position           SNP ID        Nucleotide change   AA alteration                           Type of mutation                       N° Individuals   Ref.
  ------------------ ------------- ------------------- --------------------------------------- -------------------------------------- ---------------- ----------------------------
  5246840            rs36020563    G/A                 His144His                               Synonymous                             1                \[[@pone.0174637.ref021]\]
  5246870            rs113082294   C/G                 Val134Val                               Synonymous                             9                \[[@pone.0174637.ref022]\]
  5246883            rs111645889   G/A                 Ala130Val                               Missense                               1                \[[@pone.0174637.ref023]\]
  5246890            rs33971634    G/A                 Gln128                                  Stop gained                            1                \[[@pone.0174637.ref024]\]
  5246908            rs33946267    C/G                 Glu122Gln                               Missense                               3                \[[@pone.0174637.ref025]\]
  5246947            rs33958637    T/G                 Asn109His                               Missense                               1                \[[@pone.0174637.ref026]\]
  5246948            rs193922562   G/A                 Gly108Gly                               Synonymous                             1                \[[@pone.0174637.ref027]\]
  5247876            rs145669504   G/T                 Leu82Leu                                Synonymous                             5                \[[@pone.0174637.ref028]\]
  5247992--5247996   rs281864900   CAAAG/C             Phe42fs                                 Frameshift                             5                \[[@pone.0174637.ref029]\]
  5248004            rs11549407    G/A                 Gln40                                   Stop gained                            1                \[[@pone.0174637.ref030]\]
  5248029            rs1135071     C/A                 Arg31Ser                                Splice region and missense             1                \[[@pone.0174637.ref031]\]
  5248030            rs33943001    C/G                 [\#](#t001fn001){ref-type="table-fn"}   Splice acceptor and intron variant     1                \[[@pone.0174637.ref032]\]
  5248159            rs33971440    C/T                 [\#](#t001fn001){ref-type="table-fn"}   Splice donor and intron variant        1                \[[@pone.0174637.ref033]\]
  5248162            rs35578002    G/T                 Glu30Gly                                Splice region and synonymous variant   1                \[[@pone.0174637.ref034]\]
  5248173            rs33950507    C/T                 Glu27Lys                                Missense                               14               \[[@pone.0174637.ref035]\]
  5248200            rs33986703    T/A                 Lys18                                   Stop gained                            6                \[[@pone.0174637.ref036]\]
  5248205            rs63750783    C/T                 Trp16                                   Stop gained                            2                \[[@pone.0174637.ref037]\]
  5248232            rs334         T/A                 Glu7Val                                 Missense                               137              \[[@pone.0174637.ref038]\]
  5248233            rs33930165    C/T                 Glu7Lys                                 Missense                               17               \[[@pone.0174637.ref039]\]
  5248236            rs33912272    G/A                 Pro6Ser                                 Missense                               1                \[[@pone.0174637.ref040]\]

\#---Intronic variant mutations

10.1371/journal.pone.0174637.t002

###### SNP ID, nucleotide and Amino Acid changes, number of individuals and population frequency of each mutation.

![](pone.0174637.t002){#pone.0174637.t002g}

  SNP ID        Nucleotide change   Amino Acid change   Total individuals   N°/ Freq AFR   N°/ Freq AMR   N°/ Freq EAS   N°/Freq EUR   N°/ Freq SAS   Total Allele Frequency
  ------------- ------------------- ------------------- ------------------- -------------- -------------- -------------- ------------- -------------- ------------------------
  rs36020563    G/A                 His144His           1                   1 (0.0008)     0              0              0             0              0.00019
  rs113082294   C/G                 Val134Val           9                   0              2 (0.0029)     0              7 (0.007)     0              0.00179
  rs111645889   G/A                 Ala130Val           1                   1 (0.0008)     0              0              0             0              0.00019
  rs33971634    G/A                 Gln128              1                   0              1 (0.0014)     0              0             0              0.00019
  rs33946267    C/G                 Glu122Gln           3                   0              0              0              0             3 (0.0031)     0.00059
  rs33958637    T/G                 Asn109His           1                   0              0              1 (0.001)      0             0              0.00019
  rs193922562   G/A                 Gly108Gly           1                   1 (0.0008)     0              0              0             0              0.00019
  rs145669504   G/T                 Leu82Leu            5                   0              0              5 (0.005)      0             0              0.00099
  rs281864900   CAAAG/C             Phe42fs             5                   0              0              5 (0.005)      0             0              0.00099
  rs11549407    G/A                 Gln40               1                   0              1 (0.0014)     0              0             0              0.00019
  rs1135071     C/A                 Arg31Ser            1                   0              0              0              1 (0.001)     0              0.00019
  rs33943001    C/G                 \#                  1                   0              0              0              0             1 (0.001)      0.00019
  rs33971440    C/T                 \#                  1                   0              1 (0.0014)     0              0             0              0.00019
  rs35578002    G/T                 Glu30Gly            1                   1 (0.0008)     0              0              0             0              0.00019
  rs33950507    C/T                 Glu27Lys            14                  0              0              8 (0.0079)     0             6 (0.0061)     0.00279
  rs33986703    T/A                 Lys18               6                   0              0              6 (0.006)      0             0              0.00119
  rs63750783    C/T                 Trp16               2                   0              0              0              0             2 (0.002)      0.00039
  rs334         T/A                 Glu7Val             137                 132 (0.0072)   5 (0.0998)     0              0             0              0.02735
  rs33930165    C/T                 Glu7Lys             17                  17 (0.0129)    0              0              0             0              0.00339
  rs33912272    G/A                 Pro6Ser             1                   0              0              0              1 (0.001)     0              0.00019

AFR: African.; AMR: American; EAS: Eastern Asian; EUR: European; SAS: Southern Asian.

10.1371/journal.pone.0174637.t003

###### SNP ID; nucleotide alteration; amino acid alteration; total number of individuals; list of the results from CLINVAR, dbSNP, HbVar, POLYPHEN, PROVEAN, SIFT, PANTHER, and MUTPRED; and final analysis of pathogenicity.

![](pone.0174637.t003){#pone.0174637.t003g}

  SNP ID        Nucleotide change   Amino acid change                       Total individuals   CLINVAR                                 dbSNP (NCBI)                            HbVar      POLYPHEN                                PROVEAN                                 SIFT                                    PANTHER                                 MUTPRED                                 Conclusion pathogenicity
  ------------- ------------------- --------------------------------------- ------------------- --------------------------------------- --------------------------------------- ---------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------
  rs11164588    G/A                 Ala130Val                               1                   Other                                   Other                                   Benign     Benign                                  Damaging                                Damaging                                Damaging                                Damaging                                Conflict
  rs33971634    G/A                 Gln128                                  1                   Damaging                                Other                                   Damaging   [\*](#t003fn001){ref-type="table-fn"}   Damaging                                [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs33946267    C/G                 Glu122Gln                               3                   Damaging                                Damaging                                Benign     Benign                                  Benign                                  Damaging                                Benign                                  Damaging                                Conflict
  rs33958637    T/G                 Asn109His                               1                   Other                                   [\*](#t003fn001){ref-type="table-fn"}   Benign     Probably damaging                       Damaging                                Damaging                                Benign                                  Damaging                                Conflict
  rs281864900   CAAAG/C             Phe42fs                                 5                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   Damaging                                [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs11549407    G/A                 Gln40                                   1                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs1135071     C/A                 Arg31Ser                                1                   Damaging                                Damaging                                Benign     Probably damaging                       Damaging                                Damaging                                Damaging                                Damaging                                Damaging
  rs33943001    C/G                 [\#](#t003fn002){ref-type="table-fn"}   1                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs33971440    C/T                 [\#](#t003fn002){ref-type="table-fn"}   1                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs35578002    G/T                 Glu30Gly                                1                   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging   Benign                                  Benign                                  Benign                                  Benign                                  Benign                                  Conflict
  rs33950507    C/T                 Glu27Lys                                14                  Damaging                                Damaging                                Damaging   Benign                                  Damaging                                Damaging                                Damaging                                Damaging                                Damaging
  rs33986703    T/A                 Lys18                                   6                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   Damaging                                [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs63750783    C/T                 Trp16                                   2                   Damaging                                Damaging                                Damaging   [\*](#t003fn001){ref-type="table-fn"}   Damaging                                [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   [\*](#t003fn001){ref-type="table-fn"}   Damaging
  rs334         T/A                 Glu7Val                                 137                 Damaging                                Damaging                                Damaging   Benign                                  Damaging                                Damaging                                [\*](#t003fn001){ref-type="table-fn"}   Damaging                                Damaging
  rs33930165    C/T                 Glu7Lys                                 17                  Damaging                                Damaging                                Damaging   Benign                                  Damaging                                Damaging                                [\*](#t003fn001){ref-type="table-fn"}   Damaging                                Damaging
  rs33912272    G/A                 Pro6Ser                                 1                   Other                                   Other                                   Benign     Benign                                  Benign                                  Benign                                  [\*](#t003fn001){ref-type="table-fn"}   Damaging                                Conflict

\* Could not be evaluated

\# Intronic variant mutations

3. Results {#sec003}
==========

A total of 20 different mutations were identified in 209 individuals (8.34%) in the coding region of the *HBB* gene. The variants observed were classified as follows: (i) four synonymous mutations; (ii) seven missense mutations; (iii) four stop-gain mutations; (iv) one frameshift mutation; (v) one splice region and missense variant; (vi) one splice region and synonymous variant; (vii) one splice acceptor and intron variant; and (viii) one splice donor and intron variant. Missense mutations were the most frequently encountered, affecting 174 (83.2%) individuals, as shown in [Table 1](#pone.0174637.t001){ref-type="table"}. All observed mutations were heterozygous and already had SNP IDs.

The mutations with the highest allelic frequencies were as follows: (i) rs334 had total frequency of 0.0274 (African and American populations); (ii) rs33930165 had a frequency of 0.0034 (only in the African population); and (iii) rs33950507 had a frequency of 0.0028 (Eastern and Southern Asian populations), as shown in [Table 2](#pone.0174637.t002){ref-type="table"}.

Synonymous mutations were encountered in 16 (7.6%) samples and were excluded from the investigation of pathogenicity performed by the database predictors because they do not alter the amino acid sequence.

Thus, the pathogenicity of missense, stop-gain, frameshift, splice region (both acceptor and donors), synonymous and intron mutations were tracked using the dbSNP, CLINVAR and HbVar databases, as well as five *in silico* predictors (POLYPHEN, SIFT, PROVEAN, PANTHER and MUTPRED). The results showed 11 pathogenic mutations of *HBB* ([Table 3](#pone.0174637.t003){ref-type="table"}). In addition, five mutations---(1) rs111645889, (2) rs33946267, (3) rs33958637 (4) rs35578002 and (5) rs33912272---presented conflicting results between predictors and databases.

4. Discussion {#sec004}
=============

Mutations in the *HBB* gene are distributed unevenly among the different population groups. The African population was the most affected, with 73.2% of individuals having mutations in this gene, while the European population was least affected, with 4.3% of individuals having such mutations.

The three mutations with the greatest frequency were (1) rs334 (AFR and AMR); (2) rs33930165 (AFR); and (3) rs33950507 (EAS and SAS). The rs334 mutation is responsible for hemoglobin S, known as *HbS*, which causes sickle cell anemia. The rs33930165 mutation is responsible for hemoglobin C, or *HbC* \[[@pone.0174637.ref041]\], which is more frequent in the African population \[[@pone.0174637.ref042],[@pone.0174637.ref043]\]. In addition, the rs3395057 mutation is responsible for hemoglobin E, or *HbE* \[[@pone.0174637.ref041]\], which is involved in β-thalassemia described in Asian populations \[[@pone.0174637.ref044]\].

The available data show that variants rs33986703, rs63750783, and rs281864900 are responsible for β-thalassemia and are described in Asian populations \[[@pone.0174637.ref045],[@pone.0174637.ref046],[@pone.0174637.ref039]\]. Variants rs11549407 and rs33971634 are also β-thalassemia mutations but are common in European populations \[[@pone.0174637.ref047],[@pone.0174637.ref024]\]; rs33971440 and rs35578002 are commonly found in populations of the Mediterranean region \[[@pone.0174637.ref048],[@pone.0174637.ref049],[@pone.0174637.ref034]\].

Although the *HBB* gene is well studied, there are some mutations in this gene that are not well known and poorly described in the literature. This is the case of the variants rs111645889, rs33958637, rs1135071, rs33943001 and rs33912272, for which no scientific papers were found discussing their epidemiology.

CLINVAR \[[@pone.0174637.ref018]\] is one of the most widely used databases in clinical and pathological analyses related to mutations. However, not all mutations of the *HBB* gene (rs35578002) are registered in this database, and conflicting results have been observed when comparing predictors with the CLINVAR, dbSNP and HbVar databases to estimate the pathogenicity of each mutation, or more specifically, the clinical significance of mutations rs111645889, rs33946267, rs33958637, rs35578002 and rs33912272.

It is important to emphasize that all samples deposited in the 1,000 Genomes Project, an international consortium aimed at producing a public catalog of human genetic variability, belong to individuals without clinical manifestations of any disease.

The SNP rs35578002 is not available in CLINVAR and has no information on clinical significance in the dbSNP database. Predictors consider this variant as benign, but the HbVar database classifies it as a damaging mutation. This variant is the β-thalassemia mutation Cd29 (C\> T), which in homozygosis causes hemolytic anemia and ineffective erythropoiesis \[[@pone.0174637.ref034]\]. This mutation was described in Mediterranean populations. One possible explanation for the inconsistent information about the clinical significance of this variant is that it is a synonymous mutation in the splice region that is critical for RNA processing, causing thalassemia as described in HbVar. Also noteworthy is the mutation rs33946267. According to the literature, this mutation leads to the formation of Hb D-Punjab. This mutation is generally asymptomatic but may occasionally cause moderate hemolytic anemia, similar to the manifestations of sickle cell anemia when associated with other hemoglobin variants, such as HbS or β-thalassemia mutations. Its initial distribution suggests that it is more prevalent in the central region of Asia, but due to migration, it can be found in several other regions \[[@pone.0174637.ref050]\].

According to the results, 8.3% of the phenotypically healthy individuals of the 1,000 Genomes database have a mutation in the *HBB* gene in heterozygosis. This means that eighty out of 1,000 individuals have a mutant allele in the gene. The frequency of mutated genes was estimated at 0.042, so that the expected frequency of being homozygous or compound heterozygous for these variants in the next generation is approximately 0.002. In total, 193 subjects had a non-synonymous mutation, meaning that approximately 7.7% had a change that affects the sequence of amino acids. Of these, 186 (7.4%) have a deleterious mutation based on available data on the clinical significance of these mutations ([Table 3](#pone.0174637.t003){ref-type="table"}). Considering that the 1,000 Genomes database is representative of the world's population, it can be estimated that fourteen out of every 10,000 individuals in the world will have a hemoglobinopathy in the next generation.

Independently, new studies are needed to validate the clinical consequences of the mutations with undefined pathogenicity. Considering the absence of physiopathological knowledge relative to the newly identified mutations, the use of *in silico* predictors (in an orderly and criteria-based manner) emerges as a possible tool to aid in decision-making with respect to diagnostic, preventative, and treatment measures.
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